Prosthetic Infection Clinical Trial
Official title:
Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial
Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04346875 -
Changing of Dressing for Periprosthetic Joint Infection in Total Knee Arthroplasty
|
N/A | |
| Recruiting |
NCT05060952 -
Calprotectin in Chronic Prosthetic Joint Infection
|
||
| Recruiting |
NCT05660733 -
Study of the Aortic and Large Arterial Vessel Infections
|
||
| Enrolling by invitation |
NCT04746001 -
Artificial Intelligence in the Diagnosis of Orthopaedic Conditions, Particularly Bone Tumours and Infection
|
||
| Recruiting |
NCT05164081 -
Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture
|
Phase 3 | |
| Recruiting |
NCT04488458 -
Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections
|
N/A |